PARP14 and PARP9/DTX3L regulate interferon-induced ADP-ribosylation

Research output: Contribution to journalJournal articleResearchpeer-review

Documents

  • Fulltext

    Final published version, 10.5 MB, PDF document

  • Pulak Kar
  • Chatrin Chatrin
  • Nina Đukić
  • Osamu Suyari
  • Marion Schuller
  • Kang Zhu
  • Evgeniia Prokhorova
  • Nicolas Bigot
  • Juraj Ahel
  • Elsborg, Jonas Damgaard
  • Nielsen, Michael Lund
  • Tim Clausen
  • Sébastien Huet
  • Mario Niepel
  • Sumana Sanyal
  • Dragana Ahel
  • Rebecca Smith
  • Ivan Ahel

PARP-catalysed ADP-ribosylation (ADPr) is important in regulating various cellular pathways. Until recently, PARP-dependent mono-ADP-ribosylation has been poorly understood due to the lack of sensitive detection methods. Here, we utilised an improved antibody to detect mono-ADP-ribosylation. We visualised endogenous interferon (IFN)-induced ADP-ribosylation and show that PARP14 is a major enzyme responsible for this modification. Fittingly, this signalling is reversed by the macrodomain from SARS-CoV-2 (Mac1), providing a possible mechanism by which Mac1 counteracts the activity of antiviral PARPs. Our data also elucidate a major role of PARP9 and its binding partner, the E3 ubiquitin ligase DTX3L, in regulating PARP14 activity through protein-protein interactions and by the hydrolytic activity of PARP9 macrodomain 1. Finally, we also present the first visualisation of ADPr-dependent ubiquitylation in the IFN response. These approaches should further advance our understanding of IFN-induced ADPr and ubiquitin signalling processes and could shed light on how different pathogens avoid such defence pathways.

Original languageEnglish
JournalEMBO Journal
Volume43
Issue number14
Pages (from-to)2929-2953
ISSN0261-4189
DOIs
Publication statusPublished - 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2024.

    Research areas

  • ADP-ribosylation, Immune Response, Interferon Response, SARS-CoV2, Ubiquitin

ID: 394714476